PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Down 18.0% in February

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) was the target of a significant decline in short interest in February. As of February 27th, there was short interest totaling 1,232,783 shares, a decline of 18.0% from the February 12th total of 1,503,564 shares. Currently, 2.5% of the company’s stock are short sold. Based on an average trading volume of 882,107 shares, the short-interest ratio is presently 1.4 days. Based on an average trading volume of 882,107 shares, the short-interest ratio is presently 1.4 days. Currently, 2.5% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Hedge Funds Weigh In On PMV Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Shay Capital LLC purchased a new position in PMV Pharmaceuticals in the second quarter valued at $26,000. Squarepoint Ops LLC lifted its holdings in PMV Pharmaceuticals by 101.8% during the 4th quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock worth $33,000 after buying an additional 13,367 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of PMV Pharmaceuticals by 349.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after acquiring an additional 21,334 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of PMV Pharmaceuticals during the 4th quarter worth about $79,000. Finally, Algert Global LLC purchased a new position in shares of PMV Pharmaceuticals in the 3rd quarter valued at about $87,000. Institutional investors and hedge funds own 90.20% of the company’s stock.

PMV Pharmaceuticals Stock Performance

PMVP stock opened at $1.56 on Wednesday. The company’s 50 day moving average price is $1.25 and its 200 day moving average price is $1.31. The firm has a market capitalization of $83.19 million, a price-to-earnings ratio of -1.05 and a beta of 1.27. PMV Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $1.88.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Equities analysts forecast that PMV Pharmaceuticals will post -1.06 EPS for the current fiscal year.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.